Blood peptide profiles in cats with chronic gingivostomatitis: molecular associations and limitations
Journal of veterinary internal medicine · 2026
In plain language
The study compared 34 cats with feline chronic gingivostomatitis, a condition involving inflammation in the mouth, and 18 healthy cats. It identified patterns of small proteins in the blood associated with the disease, but did not establish whether they cause it, result from it, or reflect other related factors. Both groups included FeLV-positive cats, with no statistically significant difference; this does not establish that the groups are equivalent or rule out a link between FeLV and the disease. Neither FeLV as an explanation for these patterns nor their use as validated clinical markers has been established.
Scientific detail
The study published in Journal of veterinary internal medicine in 2026 (doi: 10.1093/jvimsj/aalag169) prospectively enrolled 34 cats with histopathologically confirmed feline chronic gingivostomatitis (FCGS) and 18 healthy controls in a case-control design. This was a preliminary, single-center, cross-sectional observational study conducted in Thailand, not a randomized intervention; the clinical evidence described is level C. Three FCGS samples were excluded from the MALDI-TOF MS PLS-DA plots as outliers. The supplied text does not clearly report the final number of samples included in each subsequent analysis.
Bioinformatic analysis of the serum peptidomic profiles identified significant enrichment of JAK–STAT and PI3K-Akt signaling pathways. This claim is evidence level E: it derives from computational analysis of experimentally measured serum profiles, and direct functional confirmation of these pathways is not reported. The authors explicitly identify the molecular signatures as disease associations rather than established causal relationships. The study cannot determine whether the signatures cause FCGS, result from it, or reflect other associated factors; enrichment also does not establish causal activation or a FeLV-specific mechanism.
FeLV antigen screening was positive in 3/34 cats with FCGS and 1/18 controls, with no statistically significant difference (P = 1.0; evidence level C). This finding does not establish equivalence between the groups or exclude an association between FeLV and FCGS. The principal molecular findings concern FCGS, and the supplied text does not establish that FeLV caused the observed serum signatures or pathway enrichment.
Limitations include possible residual effects of previous medications despite a seven-day washout; no categorization by viral load, specifically FCV, or disease severity; predominant inclusion of severe active FCGS; single-center recruitment; the cross-sectional observational design; and a potentially insufficient sample size for pathway-level certainty. The authors also cite a lack of pedigreed breeds in the FCGS group, although Table 1 lists Siamese, Persian, and British Short Hair cats in that group. Independent biomarker validation and established diagnostic thresholds are lacking. Clinical utility remains unresolved: the authors call for larger independent cohorts and determination of diagnostic thresholds and performance metrics.
What we know
In this observational study of cats with FCGS and healthy controls, serum peptide signatures are described as disease associations, not established causal relationships (level C). Computational analysis identified significant enrichment of JAK–STAT and PI3K-Akt, without reported direct functional confirmation (level E). FeLV screening positivity was 3/34 versus 1/18, with no statistically significant difference (P = 1.0; level C), which neither establishes equivalence nor excludes an association.
What we don't know
Whether the serum signatures cause FCGS, result from it, or reflect other associated factors is unknown. FeLV has not been established as a cause of the signatures or pathway enrichment, and direct functional confirmation of these pathways has not been reported. The signatures' utility as validated clinical biomarkers is also unestablished: larger independent cohorts, diagnostic thresholds, and performance metrics are still needed. The final sample count for each analysis following outlier exclusion is not clearly reported.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The authors explicitly state that the identified molecular signatures are disease associations rather than established causal relationships.
Excerpt verified in the source — verbatim, in the source's own language“Given its cross-sectional, observational design, the molecular signatures identified should be regarded as associations with the disease condition rather than as specific causal relationships.”
This limitation constrains the stronger mechanistic language elsewhere in the paper. The study cannot establish whether the signatures cause FCGS, result from it, or reflect other associated factors.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The study enrolled 34 cats with histopathologically confirmed FCGS and 18 healthy controls in a prospective case-control design.
Excerpt verified in the source — verbatim, in the source's own language“In our prospective case–control study, 34 cats with caudal stomatitis and histopathologically confirmed FCGS and 18 healthy controls (CTRL) were enrolled.”
This establishes the enrolled comparison groups, not a randomized intervention study. Level C reflects a preliminary, single-center observational study without independent validation.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
FeLV screening positivity was not significantly different between FCGS cats and controls, with 3/34 versus 1/18 positive cats and P = 1.0.
Excerpt verified in the source — verbatim, in the source's own language“Similarly, the frequency of FeLV infection was not significantly different between the groups (FCGS: 3/34 vs CTRL: 1/18; P = 1.0).”
This reports a nonsignificant comparison of screening positivity in this cohort. It does not establish equivalence between groups or exclude an association between FeLV and FCGS.
EvidenceLevel E — Computational hypothesisConfidence 100/100
Bioinformatic analysis of the serum peptidomic findings identified significant enrichment of JAK–STAT and PI3K-Akt signaling pathways.
Excerpt verified in the source — verbatim, in the source's own language“Key inflammatory signaling cascades, including the JAK–STAT (FDR: 1.39 × 10 −8 ) and PI3K-Akt (FDR: 3.42 × 10 −8 ) signaling pathways, were significantly enriched, reinforcing their potential roles in disease development and consistent with previous findings in saliva of affected cats.”
The enrichment is computational analysis of experimentally measured serum profiles. Level E applies to the pathway-level claim because direct functional confirmation of these pathways is not reported. Enrichment does not establish causal activation or a FeLV-specific mechanism.
Open questionConfidence 100/100
Whether these serum peptide signatures can serve as validated clinical biomarkers remains unresolved.
The authors call for larger independent validation cohorts and determination of diagnostic thresholds and performance metrics; clinical diagnostic utility is not established.
Provenance
Source: Serum peptidomic profiling identifies systemic JAK-STAT and PI3K-Akt pathway dysregulation in cats with chronic gingivostomatitis.
AVA